Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
Q3 2024 Financial Performance Overview
Eli Lilly's earnings report for Q3 2024 revealed a revenue of $11.4 billion, an increase of 20% year-over-year. However, despite the growth, the results missed analyst expectations, raising concerns about future performance.
Supply Chain Challenges Affecting Results
The ongoing supply chain challenges have been a significant factor in Eli Lilly's financial outcomes. With a net income of $970 million after expenses, the company is navigating a complex landscape that influences its profitability.
- Revenue: $11.4 billion
- Year-over-Year Growth: 20%
- Net Income: $970 million
Market Implications
Investors are keenly watching Eli Lilly's response to these challenges as they reflect on broader market trends. An in-depth analysis of this earnings report offers insights into industry dynamics.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.